Registration Dossier

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Link to relevant study record(s)

Description of key information

No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.

However, as per REACH guidance document R7.C , information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties and QSAR predictions.

Based on the physical-chemical properties and QSAR predictions, the absorption of 3.3.5-trimethylcyclohexyl methacrylate is expected to be high by oral route and inhalation, but low by dermal route. A good distribution and excretion of the substance are expected.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
100
Absorption rate - dermal (%):
10
Absorption rate - inhalation (%):
100

Additional information

No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate. However, as per REACH guidance document R7.C, information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties, including:

-Mean molecular weight: 218 g/mol

-Water solubility: 86 mg/L

-Partition coefficient Log Kow: 2.5

-Vapour pressure: 0.000288 Pa (25°C)

 

ABSORPTION

Oral absorption: The moderate values of log Kow (2-4), the moderate solubility and the moderate molecular weight (below 500 g/mol) of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate are favorable for an oral absorption. The oral absorption is confirmed in the acute toxicity study, in which severe clinical signs and mortality were observed at 2000 mg/kg bw.The worst case value (100%) is used as oral absorption for the risk assessment.

Dermal absorption: With a low solubility of 86 mg/L and a moderate log Kow, dermal absorption is anticipated to be moderate to high. However, according to the IH skin perm (QSAR), the dermal absorption of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is very low (<10%). The substance showed allergic reaction in the LLNA: it is evidence that some uptake must have occurred although it may only have been a small fraction of the applied dose.For the risk assessment, 10% of dermal absorption is taken into account.

 Inhalation absorption: Based on the low value of the vapour pressure (< 0.001 Pa), 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is considered as a low volatile substance.For the risk assessment, 100% of inhalation absorption is taken into account.

 

DISTRIBUTION and METABOLISM

No specific data is available on the distribution or metabolism of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.

 

ELIMINATION

Due to the moderate molecular weight (< 300), the moderate water solubility and the moderate log kow, the excretion of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate in the urines is expected.